Clinical trials: Abscopal Effect
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
Patients with Non-small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Radiotherapy, Thymalfasin
- Trial name
- NCT02542930
- Testing
- Radiotherapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Advanced Solid Tumors
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
The therapeutic approach taken by trial SAKK 66/17 is different from those already used in clinical practice and possibly offers patients a therapeutic benefit after failure of standard chemotherapy and immunotherapy.
- Trial name
- NCT03993678
- Testing
- IP-001, Thermal Ablation
- Where
- 3 sites in Switzerland
- Volunteers
- 28 people
- Sponsor
- Swiss Cancer Institute
Soft Tissue Sarcoma Adult
Radiation Effects on Bone
Post-radiotherapy fragility fractures (caused by weakened bones) are an occasional complication of orthopedic oncology of soft tissue sarcoma patients.
- Trial name
- NCT03134742
- Testing
- Control Group, CT Scan, DEXA Scans
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- State University of New York - Upstate Medical University
Neoplasms, Secondary Malignant Neoplasm
Abscopal Effect from the Low-dose Radiotherapy in Polymetastatic Cancer Patients Receiving Stereotactic Radiotherapy
Recently, MD Anderson Cancer Center reported the phase II trial to investigate high-dose radiotherapy (HDRT, 20-70 Gy) and low-dose radiotherapy (LDRT, 1-10 Gy) for metastatic cancer patients who had undergone immunotherapy.
- Trial name
- KROG22-11 (NCT05733156)
- Testing
- SBRT + LDRT
- Where
- 2 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- Soonchunhyang University Hospital
Melanoma
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
This study is a phase I/II, multicenter, open-label study starting with a phase I part followed by a Phase II part. The phase I part of the study aims at evaluating the safety and efficacy (in terms of abscopal effect at week 6)…
- Trial name
- NCT03354962
- Testing
- Nivolumab + Ipilimumab, Combined treatment schema
- Where
- 6 sites in France
- Volunteers
- 6 people
- Sponsor
- Institut Claudius Regaud
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and…
- Trial name
- FUSION NHL 001 (NCT02733042)
- Testing
- Durvalumab, Lenalidomide, Rituximab
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 106 people
- Sponsor
- Celgene
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach
- Trial name
- NCT02830594
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Lung Cancer Metastatic
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the…
- Trial name
- NCT02976740
- Testing
- SBRT, Immunological Agent, Immunological Factors
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
Classical Hodgkin Lymphoma
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy
The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy.
- Trial name
- AERN (NCT03480334)
- Testing
- Nivolumab plus radiotherapy
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- University of Cologne
Neoplasms, Secondary Malignant Neoplasm
Abscopal Effect From Low-dose Radiotherapy in Metastatic Cancer Combined With Stereotactic Body Radiotherapy
Stereotactic body radiotherapy (SBRT) has been known to enhance the abscopal effect by up to 40% when delivered with immune checkpoint inhibitors (ICIs).
- Trial name
- NCT05578274
- Testing
- SBRT + LDRT, SBRT alone
- Sponsor
- Soonchunhyang University Hospital
Metastatic Breast Cancer
Fresolimumab and Radiotherapy in Metastatic Breast Cancer
The purpose of this study is to test safety of combining fresolimumab and local radiotherapy and to see if the combination can achieve tumor regression.
- Trial name
- NCT01401062
- Testing
- Fresolimumab, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Weill Medical College of Cornell University
Pancreas Cancer
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
The trial investigates the safety and efficacy of irreversible electroporation in combination with checkpoint inhibition in patients with metastatic pancreatic cancer.
- Trial name
- CHECKPOINT (NCT05435053)
- Testing
- Nivolumab, Irreversible electroporation (IRE)
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Ismail Gögenur
Small Cell Lung Cancer, Radiotherapy
Abscopal Effect for Metastatic Small Cell Lung Cancer
Patients with small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Small Cell Lung Cancer, Radiotherapy, Thymalfasin
- Trial name
- NCT02542137
- Testing
- Radiotherapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Melanoma, Effects of Immunotherapy
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
The prognosis of advanced metastatic melanoma remains poor although a breakthrough has been achieved with the novel anti-CTLA-4 treatment (ipilimumab) for a subset of patients.
- Conditions
- Melanoma, Effects of Immunotherapy, Adverse Effect of Radiation Therapy
- Trial name
- NCT02406183
- Testing
- Stereotactic body radiotherapy (SBRT), Ipilimumab
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- Radiotherapie
NSCLC Stage IV Without EGFR/ALK Mutation
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases.
- Trial name
- NCT06947694
- Testing
- chemotherapy + PD-1 inhibitors
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Xinqiao Hospital of Chongqing
Colorectal Cancer (CRC), Colon Cancer Liver Metastases
Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases
The goal of this clinical trial is to learn if a new injectable drug (IP-001), administered after standard liver tumor ablation, can help prevent cancer from returning in people (males/females, ≥18 years old) with colorectal…
- Conditions
- Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer, Rectal Cancer With Liver Metastases
- Trial name
- INJECTABL-3 (NCT07321847)
- Testing
- 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water, 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water., Microwave (thermal) tumor ablation
- Volunteers
- 717 people
- Sponsor
- Immunophotonics, Inc.
Solid Tumor, Lymphoma
An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce immunogenic death of tumor cells and a stronger immune response.
- Trial name
- NCT04873440
- Testing
- Manganese Chloride, Radiotherapy, Chemo-immunotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Bystander Effect, Abscopal Effect
SBRT-based PArtial Tumor Irradiation of HYpoxic Segment
This study uses an unconventional radiotherapy schedule developed at our institute, consisting of a short course high-dose partial irradiation targeting exclusively the hypoxic segment of a bulky tumors, which in our preliminary…
- Conditions
- Bystander Effect, Abscopal Effect, Unresectable Malignant Solid Neoplasm, Bulky Tumors
- Trial name
- SBRT-PATHY (NCT04168320)
- Testing
- SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Klinikum Klagenfurt am Wörthersee
Metastatic Colorectal Cancer
Electroporation and Immunotherapy in Metastatic Colorectal Cancer
The trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium electroporation (CaEP) performed concurrently…
- Trial name
- ELI (NCT05609656)
- Testing
- Irreversible electroporation, Calcium electroporation, Pembrolizumab
- Where
- Denmark
- Volunteers
- 4 people
- Sponsor
- Ismail Gögenur